Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
← catalyst calendarNCT06812104 · readout in 1,929 d
Sponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
156estimated
Sites
17
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-10 | actual | When the study began enrolling |
| Primary completion | 2031-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed or Refractory AML and Other Hematologic Malignancies
Interventions
- Drug: KK2845_1
- Drug: KK2845_2
- Drug: KK2845_3
- Drug: KK2845_4
- Drug: KK2845_5
- Drug: KK2845_6
- Drug: KK2845_7
- Drug: KK2845_8
- Drug: KK2845_alternative_1
- Drug: KK2845_alternative_2
Primary outcome
what the primary-completion date above is the date OFDose-limiting toxicity (Part 1：Dose escalation)
measured At the end of Cycle 1 (each cycle is 21 or 28 days)
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed